Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373959" target="_blank" >RIV/00216208:11130/17:10373959 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/17:00097296 RIV/00159816:_____/17:00067088 RIV/00064203:_____/17:10373959

Výsledek na webu

<a href="https://doi.org/10.1016/j.jcin.2017.03.030" target="_blank" >https://doi.org/10.1016/j.jcin.2017.03.030</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jcin.2017.03.030" target="_blank" >10.1016/j.jcin.2017.03.030</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy

Popis výsledku v původním jazyce

Objectives The aim of this study was to describe the safety and outcomes of alcohol septal ablation (ASA) in younger patients with obstructive hypertrophic cardiomyopathy. Background The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for older patients and patients with serious comorbidities. Data on long-term age-specific outcomes after ASA are scarce. Methods A total of 1,197 patients (mean age 58 +- 14 years) underwent ASA for obstructive hypertrophic cardiomyopathy. Patients were divided into young (LESS-THAN OR EQUAL TO50 years), middle-age (51 to 64 years), and older (GREATER-THAN OR EQUAL TO65 years) groups. Results Thirty-day mortality and pacemaker implantation rates were lower in young compared with older patients (0.3% vs. 2% [p = 0.03] and 8% vs. 16% [p &lt; 0.001], respectively). Ninety-five percent of young patients were in New York Heart Association functional class I or II at last follow-up. During a mean follow-up period of 5.4 +- 4.2 years, 165 patients (14%) died. Annual mortality rates of young, middle-age, and older patients were 1%, 2%, and 5%, respectively (p &lt; 0.01). Annual adverse arrhythmic event rates were similar in the 3 age groups at about 1% (p = 0.90). Independent predictors of mortality in young patients were age, female sex, and residual left ventricular outflow tract gradient. Additionally, young patients treated with GREATER-THAN OR EQUAL TO2.5 ml alcohol had a higher all-cause mortality rate (0.6% vs. 1.4% per year in patients treated with &lt;2.5 ml, p = 0.03). Conclusions ASA in younger patients with obstructive hypertrophic cardiomyopathy was safe and effective for relief of symptoms at long-term follow-up. The authors propose that the indication for ASA can be broadened to younger patients.

Název v anglickém jazyce

Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy

Popis výsledku anglicky

Objectives The aim of this study was to describe the safety and outcomes of alcohol septal ablation (ASA) in younger patients with obstructive hypertrophic cardiomyopathy. Background The American College of Cardiology Foundation/American Heart Association guidelines reserve ASA for older patients and patients with serious comorbidities. Data on long-term age-specific outcomes after ASA are scarce. Methods A total of 1,197 patients (mean age 58 +- 14 years) underwent ASA for obstructive hypertrophic cardiomyopathy. Patients were divided into young (LESS-THAN OR EQUAL TO50 years), middle-age (51 to 64 years), and older (GREATER-THAN OR EQUAL TO65 years) groups. Results Thirty-day mortality and pacemaker implantation rates were lower in young compared with older patients (0.3% vs. 2% [p = 0.03] and 8% vs. 16% [p &lt; 0.001], respectively). Ninety-five percent of young patients were in New York Heart Association functional class I or II at last follow-up. During a mean follow-up period of 5.4 +- 4.2 years, 165 patients (14%) died. Annual mortality rates of young, middle-age, and older patients were 1%, 2%, and 5%, respectively (p &lt; 0.01). Annual adverse arrhythmic event rates were similar in the 3 age groups at about 1% (p = 0.90). Independent predictors of mortality in young patients were age, female sex, and residual left ventricular outflow tract gradient. Additionally, young patients treated with GREATER-THAN OR EQUAL TO2.5 ml alcohol had a higher all-cause mortality rate (0.6% vs. 1.4% per year in patients treated with &lt;2.5 ml, p = 0.03). Conclusions ASA in younger patients with obstructive hypertrophic cardiomyopathy was safe and effective for relief of symptoms at long-term follow-up. The authors propose that the indication for ASA can be broadened to younger patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JACC: Cardiovascular Interventions

ISSN

1936-8798

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1134-1143

Kód UT WoS článku

000402974900013

EID výsledku v databázi Scopus

2-s2.0-85020231314